Assunta Cirella

Cancer immunotherapy

[Assunta Cirella @CirellaAssunta]

Thrilled to share our new paper recently published in #MTNA . We developed chimeric molecules based on the mRNA technology to explore the potential synergistic effects of TGF-β neutralization and immunostimulation via IL-12R and CD137 ligation.

[Molecular Therapy Family of Journals @MolTherapy]

Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists and TGF-β antagonists. #MTNA https://t.co/H9pmodaULV

[Tumour Treg Targeting ITN @TregItn]

📢OFERTA #empleo 🚨 Plaza abierta de #Bioinformático 🖥 en el laboratorio de Inmunoterapia traslacional🧬 del @DrIgMelero en el 📍@CIMA_unav Interesados enviar CV 📩 [email protected]

[Assunta Cirella @CirellaAssunta]

It was a great pleasure to attend the EACR conference and to present our work in the poster session! Amazing talks and great opportunity to learn and network.
Looking forward to the next one!
@EACRnews
#eacrImmunoOncology

[Cancer Immunology Research @CIR_AACR]

New in the February issue - Intratumoral Gene Transfer of #mRNAs Encoding IL12 in Combination with Decoy-Resistant IL18 Improves Local and Systemic Antitumor Immunity. Study by A. Cirella, E. Bolanos, P. Berraondo, I. Melero et al.
https://t.co/4HVZleievC
@claditti @CIMA_unav

[Assunta Cirella @CirellaAssunta]

So excited to share our last work recently published in @CIR_AACR. We report on the intratumoral administration of mRNAs encoding Interleukin-12 and a decoy-resistant Interleukin-18. Congrats to all the authors!!
Read more 👉🏼https://t.co/fqpuBmDXHG

[Cancer Immunology Research @CIR_AACR]

#Intratumoral gene transfer of mRNAs encoding interleukin-12 in combination with decoy-resistant #interleukin-18 improves local & systemic antitumor immunity, by Assunta Cirella, Elixabet Bolaños, Pedro Berraondo, Ignacio Melero et al
https://t.co/TBtfSC6u9h
@claditti @KBerraondo

[ACIR @ACIR_org]

SPOTLIGHT: Depletion of conventional type-1 dendritic cells in established tumors suppresses [...] @Teijeira_ITLive @DrIgMelero @CIMA_unav @ClinicaNavarra. Originally published in @CR_AACR. To read our summary click https://t.co/w58vLojAvE and scroll all the way down.

[Journal of Experimental Medicine @JExpMed]

Karmele Valencia, Luis M. Montuenga @unav and colleagues identify DSTYK, a dual serine/threonine and tyrosine #kinase, as a novel actionable target that is altered in #LungCancer and associated with poor clinical outcome https://t.co/pdg0CeEQdj

#SolidTumors

[ACIR @ACIR_org]

So many fantastic talks at #CIMT2022! Which one inspired you the most? => https://t.co/ZC4Q4ZphyP. Speakers and institutions represented:@C_IMT @VHIO @LudwigInstitute @Uniklinikum_ER @LeibnizWGL @TIL_Radboudumc @DKTK_ @kochinstitute @MeganBurgerPhD

[Cancer Immunotherapy @C_IMT]

What happened in Mainz at #CIMT2022? Read the ACIR special report from the CIMT Annual Meeting https://t.co/Jpj7WhJY37

[Tumour Treg Targeting ITN @TregItn]

Próximo 4 de Julio🗓️ “LA INMUNOLOGÍA DEL CÁNCER HABLA EN ESPAÑOL🇪🇸” se reúne en 📍Madrid. Inscripciones📲: https://t.co/NvnqX0M7Gb
@ClinicaNavarra @CIMA_unav @bmsnews @DrIgMelero #cancerimmunotherapyday

[Assunta Cirella @CirellaAssunta]

So grateful and honoured for having had the opportunity to hold an oral presentation in "Improving immunity" short-talk session at @C_IMT. Thanks to the organizers for such an amazing conference!

#CIMT2022 #CancerImmunotherapy #mRNA

[Cancer Discovery @CD_AACR]

From the May issue: GEN1046, a bispecific antibody targeting PD-L1 and 4-1BB, by Alexander Muik, Ugur Sahin, Maria Jure-Kunkel, @DrIgMelero et al.
https://t.co/KDgEifV4Kw
@Genmab @BioNTech_Group @ClinicaNavarra @CIMA_unav

[Assunta Cirella @CirellaAssunta]

Very thrilled to share our latest review on IL-12-based applications in cancer immunotherapy! Thanks to all the authors and to @carlosluri_ for the amazing illustrations!

Check it out 👇
https://t.co/OHyk9nwKhP

[Cancer Discovery @CD_AACR]

#ICYMI: Preclinical Characterization & Phase I Trial Results of Bispecific Antibody Targeting PD-L1 & 4-1BB in Patients w/ Advanced Refractory Solid Tumors by Muik, Sahin, Jure-Kunkel, @DrIgMelero et al.
https://t.co/mkmpDIJHZ9
@Genmab @BioNTech_Group @ClinicaNavarra @CIMA_unav

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies https://t.co/d3n3PpDKEn @GuedanS @DrIgMelero

[Alvaro Teijeira Sanchez @Teijeira_ITLive]

Our small contribution to the use of #organoids in Immunoncology is now published.
https://t.co/mBuVoqX7Yo
In collaboration with @Roche we have used co-cultures of colon cancer patient derived organoids with T cells and assayed sensitivity to T-cell-engagers

[Elizabeth McKenna @ElizSMcKenna]

Now in @CD_AACR: Preclinical Characterization & Phase I Trial of a PD-L1 & 4-1BB (GEN1046) #BispecificAntibody in Advanced Refractory Solid Tumors - by Ugur Sahin, Maria Jure-Kunkel, @DrIgMelero et al @Genmab @BioNTech_Group @ClinicaNavarra @CIMA_unav https://t.co/WgVr6nUWAZ

[Cima Universidad de Navarra @CIMA_unav]

Investigadores del @CIMA_unav desvelan un importante mecanismo para entender y diseñar inmunoterapias basadas en la estimulación de CD137.
👉Un proyecto coordinado por el @DrIgMelero, en colaboración con @AlligatorBio y #Aptevo, y publicado en @NatureComms
https://t.co/RFHVFWWSh9

[Cima Universidad de Navarra @CIMA_unav]

Una nueva combinación de #inmunoterapia permite erradicar lesiones tumorales locales y a distancia en modelos animales
Un estudio coordinado por @DrIgMelero, en colaboración con @Highlight_HLT y publicado en @jitcancer 🙌
https://t.co/ujo4wmoebe

[CaixaResearch @CaixaResearch]

🔝Ignacio @DrIgMelero está considerado como el principal referente de la inmunoterapia del cáncer en España.

Lee en este artículo cómo emprendió este camino hace 20 años, en un momento en que no había ninguna certeza de adónde llevarían estos fármacos
https://t.co/FqK1E5Ga1I